Herausragende Publikationen
2022
Human β-defensin 2 ameliorates acute GVHD by limiting ileal neutrophil infiltration and restraining T cell receptor signaling.
Rückert T, Andrieux G, Boerries M, Hanke-Müller K, Woessner NM, Doetsch S, Schell
C, Aumann K, Kolter J, Schmitt-Graeff A, Schiff M, Braun LM, Haring E, Kissel S,
Siranosian BA, Bhatt AS, Nordkild P, Wehkamp J, Jensen BAH, Minguet S, Duyster J,
Zeiser R, Köhler N.
Sci Transl Med. 2022 Dec 21;14(676):eabp9675.
Targeting MDM2 enhances anti-leukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation.
Ho JNHG, Schmidt D, Lowinus T, Ryoo J, Dopfer EP, Gonzalo Núñez N, Costa-Pereira S, Toffalori C, Punta M, Fetsch V, Wertheimer T, Rittmann MC, Braun LM, Follo M, Briere C, Vinnakota JM, Langenbach M, Koppers F, Shoumariyeh K, Engel H, Rückert T, Märklin M, Holzmayer S, Illert AL, Magon F, Andrieux G, Duquesne S, Pfeifer D, Staniek J, Rizzi M, Miething C, Köhler N, Duyster J, Menssen HD, Boerries M, Buescher JM, Cabezas-Wallscheid N, Blazar BR, Apostolova P, Vago L, Pearce EL, Becher B, Zeiser R.
Blood. 140, 1167-1181 (2022). DOI: 10.1182/blood.2022016082
Begleitet von diesem Editorial:
MDM2 inhibition augments GVL effect.
Bleakley M, Biernacki M.
Blood. 2022 Sep 8;140(10):1064-1065. DOI: 10.1182/blood.2022017724
Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research.
Eliza M. Lauer*, Jurik Mutter*, and Florian Scherer.
Leukemia. 2022. doi.org/10.1038/s41375-022-01618-w
Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma.
Waldschmidt JM, Yee AJ, Vijaykumar T, Pinto RA, Frede J, Anand P, Bianchi G, Guo G, Potdar S, Seifer C, Nair MS, Kokkalis A, Kloeber JA, Shapiro S, Budano L, Mann M, Friedman R, Lipe B, Campagnaro E, O'Donnell EK, Zhang CZ, Laubach JP, Munshi NC, Richardson PG, Anderson KC, Raje NS, Knoechel B, Lohr JG.
Leukemia. 2022 Jan 13. doi: 10.1038/s41375-021-01492-y. Online ahead of print. PMID: 35027656
Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial
Zeiser R, Socié G, Schroeder MA, Abhyankar S, Vaz CP, Kwon M, Clausen J, Volodin L, Giebel S, Chacon MJ, Meyers G, Ghosh M, Deeren D, Sanz J, Morariu-Zamfir R, Arbushites M, Lakshminarayanan M, Barbour AM, Chen YB.
Lancet Haematol. 2022 Jan; 9(1):e14-e25. doi: 10.1016/S2352-3026(21)00367-7.
Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia.
El Khawanky N, Hughes A, Yu W, Myburgh R, Matschulla T, Taromi S, Aumann K, Clarson J, Vinnakota JM, Shoumariyeh K, Miething C, Lopez AF, Brown MP, Duyster J, Hein L, Manz MG, Hughes TP, White DL, Yong ASM, Zeiser R.
Nature Commun. 2021 Nov 8;12(1):6436. doi: 10.1038/s41467-021-26683-0 | www.nature.com/articles/s41467-021-26683-0
The IL-3, IL-5, and GM-CSF Common Receptor Beta Chain Mediates Oncogenic Activity of FLT3-ITD-Positive AML.
Charlet, A.*, Kappenstein, M.*, Keye, P., Kläsener, K., Endres, C., Poggio, T., Gorantla, S. P., Kreutmair, S., Sänger, J., Illert, A. L., Miething, C., Reth, M., Duyster, J., Rummelt, C.*, von Bubnoff, N.*
* contributed equally
Leukemia 2021, 1–11 | www.nature.com/articles/s41375-021-01462-4
Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine.
Oberhardt V, Luxenburger H, Kemming J, Schulien I, Ciminski K, Giese S, Csernalabics B, Lang-Meli J, Janowska I, Staniek J, Wild K, Basho K, Marinescu MS, Fuchs J, Topfstedt F, Janda A, Sogukpinar O, Hilger H, Stete K, Emmerich F, Bengsch B, Waller CF, Rieg S, Sagar, Boettler T, Zoldan K, Kochs G, Schwemmle M, Rizzi M, Thimme R, Neumann-Haefelin C, Hofmann M.
Nature. 2021 Sep;597(7875):268-273. doi: 10.1038/s41586-021-03841-4. Epub 2021 Jul 28. PMID: 34320609 | Mehr
Non-classical manifestations of acute GVHD.
Zeiser R, Teshima T.
Blood. 2021 Sep 5:blood.2021012431. doi: 10.1182/blood.2021012431 | Mehr
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F; REACH3 Investigators.
N Engl J Med. 2021 Jul 15;385(3):228-238. Mehr
CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues.
Yu X, Munoz-Sagredo L, Streule K, Muschong P, Bayer E, Walter RJ, Gutjahr JC, Greil R, Concha ML, Müller-Tidow C, Hartmann TN, Orian-Rousseau V.
Blood. 2021 Jun 3:blood.2020006343. doi: 10.1182/blood.2020006343. Online ahead of print. Mehr
Invariant Natural Killer T Cell Subsets Have Diverse Graft-Versus-Host-Disease-Preventing and Anti-Tumor Effects
Kristina Maas-Bauer, Juliane K Lohmeyer, Toshihito Hirai, Teresa Lopes Ramos, Furqan Muhammad Fazal, Ulrike M Litzenburger, Kathryn E Yost, Jessica V Ribado, Neeraja Kambham, Arielle Wenokur, Po-Yu Lin, Maite Alvarez, Melissa Mavers, Jeanette Baker, Ami S Bhatt, Howard Chang, Federico Simonetta, Robert S Negrin.
Blood. 2021 May 25;blood.2021010887. doi: 10.1182/blood.2021010887. Online ahead of print. Mehr
Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies.
Stomper J, Rotondo JC, Greve G, Lübbert M.
Leukemia. 2021 May 6. doi: 10.1038/s41375-021-01218-0. Online ahead of print. Mehr
Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma
Alig S*, Macaulay CW*, Kurtz DM*, Dührsen U, Hüttmann A, Schmitz C, Jin MC, Sworder BJ, Garofalo A, Shahrokh Esfahani M, Nabet BY, Soo J, Scherer F, Craig AFM, Casasnovas O, Westin JR, Gaidano G, Rossi D, Roschewski M, Wilson WH, Meignan M, Diehn M, and Alizadeh AA.
J Clin Oncol. 2021 Apr 28
JCO2002573. doi: 10.1200/JCO.20.02573. PMID: 33909455 Mehr
IL-33 expression in response to SARS-CoV-2 correlates with seropositivity in COVID-19 convalescent individuals
Stanczak MA#, Sanin DE#, Apostolova P#, Nerz G, Lampaki D, Hofmann M, Steinmann D, Krohn-Grimberghe M, Thimme R, Mittler G, Waller CF#*, Pearce EJ#*, Pearce EL#*.
# equal contribution | * co-corresponding
Nat Commun. 2021 Apr 9;12(1):2133. doi: 10.1038/s41467-021-22449-w. Mehr
Releasing the brake in CAR natural killer cells
Sophia Chen
Blood (2021) 137 (5): 579–581. Mehr
Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans.
Uhl FM, Chen S, O'Sullivan D, Edwards-Hicks J, Richter G, Haring E, Andrieux G, Halbach S, Apostolova P, Büscher J, Duquesne S, Melchinger W, Sauer B, Shoumariyeh K, Schmitt-Graeff A, Kreutz M, Lübbert M, Duyster J, Brummer T, Boerries M, Madl T, Blazar BR, Groß O, Pearce EL, Zeiser R.
Science Translational Med. 2020 Oct 28;12(567):eabb8969. ►
Glucagon like peptide-2 for Intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans.
Norona J, Apostolova P, Schmidt D, Ihlemann R, Reischmann N, Taylor G, Köhler N, de Heer J, Heeg S, Andrieux G, Siranosian BA, Schmitt-Graeff A, Pfeifer D, Catalano A, Frew I, Proietti M, Grimbacher B, Bulashevska A, Bhatt AS, Brummer T, Clauditz TS, Zabelina T, Kroeger N, Blazar BR, Boerries M, Ayuk F, Zeiser R.
Blood. 2020 Jun 15:blood.2020005957.
► doi.org/10.1182/blood.2020005957
Die Publikation wurde als Cover für das Journal "Blood" ausgewählt und von einem Editorial begleitet: ► https://ashpublications.org/blood/issue/136/12
Herzlichen Glückwunsch!
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Socié G, for the REACH2 Trial Group.
The New England Journal of Medicine Apr 22. ► doi: 10.1056/NEJMoa1917635 (2020).
Loss of the Fanconi anemia-associated protein NIPA causes bone marrow failure.
Kreutmair S, Erlacher M, Andrieux G, Istvanffy R, Mueller-Rudorf A, Zwick M, Rückert T, Pantic M, Poggio T, Shoumariyeh K, Mueller TA, Kawaguchi H, Follo M, Klingeberg C, Wlodarski M, Baumann I, Pfeifer D, Kulinski M, Rudelius M, Lemeer S, Kuster B, Dierks C, Peschel C, Cabezas-Wallscheid N, Duque-Afonso J, Zeiser R, Cleary ML, Schindler D, Schmitt-Graeff A, Boerries M, Niemeyer CM, Oostendorp RA, Duyster J, Illert AL.
J Clin Invest. 2020 Apr 27. pii: 126215. ► doi: 10.1172/JCI126215.
TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia
Szenes E, Härzschel A, Decker S, Tissino E, Pischeli J, Gutjahr JC, Kissel S, Pennisi S, Höpner JP, Egle A, Zaborsky N, Dierks C, Follo M, Chigaev A, Zucchetto A, Greil R, Gattei V, Hartmann TN
Leukemia. 2020 Feb 21. doi: 10.1038/s41375-020-0759-3. [Epub ahead of print]
Extracorporeal Photopheresis for Colitis Induced by Checkpoint-Inhibitor Therapy.
Apostolova P, Unger S, von Bubnoff D, Meiss F, Becher B, Zeiser R.
N Engl J Med. 2020 Jan 16;382(3):294-296.
► www.nejm.org/doi/full/10.1056/NEJMc1912274
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression
Tissino E, Pozzo F, Benedetti D, Caldana C, Bittolo T, Rossi FM, Bomben R, Nanni P, Chivilò H, Cattarossi I, Zaina E, Norris K, Polesel J, Gentile M, Tripepi G, Moia R, Santinelli E, Innocenti I, Olivieri J, D'Arena G, Laurenti L, Zaja F, Pozzato G, Chiarenza A, Di Raimondo F, Rossi D, Pepper C, Hartmann TN, Gaidano G, Del Poeta G, Gattei V, Zucchetto A.
Blood. 2020 Jan 31. pii: blood.2019003179. doi: 10.1182/blood.2019003179. [Epub ahead of print]
► ashpublications.org/blood/article-lookup/doi/10.1182/blood.2019003179
Graft-versus-host disease of the CNS is mediated by TNF upregulation in microglia.
Mathew N, Vinnakota JM, Apostolova P, Erny D, Hamarsheh S, Andrieux G, Kim JS, Hanke K, Goldmann T, Chappell-Maor L, El-Khawanky N, Ihorst G, Schmidt D, Duyster J, Finke J, Blank T, Boerries M, Blazar BR, Jung S, Prinz M, Zeiser R.
J Clin Invest. 2019 Dec 17. pii: 130272. doi: 10.1172/JCI130272.